91893-83-3
Chemical Structure
Garcinoic acid
- CAS No.: 91893-83-3
- Formula:C27H38O4
- Molecular Weight:426.59
IUPAC Name: (2E,6E,10E)-13-((R)-6-hydroxy-2,8-dimethylchroman-2-yl)-2,6,10-trimethyltrideca-2,6,10-trienoic acid
InChIKey: QOFWRHWADNWKSU-LRXIOGKNSA-N
SMILES: CC1=C2C(CC[C@](C)(O2)CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/C(O)=O)=CC(O)=C1
Biological Activity: Garcinoic acid is an orally active anti-inflammatory agent that crosses the blood-brain barrier. Garcinoic acid also enhances efferocytosis and enzyme/receptor regulation, and selectively inhibits human COX-2, porcine α-amylase, Saccharomyces cerevisiae α-glucosidase and human DNA polymerase β (IC50=11 μM), as well as activates human PXR. Garcinoic acid enhances macrophage efferocytosis via receptors such as MerTK and LRP-1, and promotes the production of pro-resolving lipid mediators. Garcinoic acid inhibits NF-κB activation and pro-inflammatory cytokine secretion, interferes with Aβ aggregation, downregulates NLRP3 inflammasome activity, and binds to targets including CD44 and EGFR to inhibit leukemia cell proliferation. The pharmacological activities of Garcinoic acid, such as antioxidant, anti-inflammatory and lipid metabolism-regulating effects, are widely used in studies related to various diseases including atherosclerosis, Alzheimer's disease, type 2 diabetes, inflammatory bowel disease and viral pneumonia[1][2][3][4][5][6][7].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Garcinoic acid | Garcinoic acid is an orally active anti-inflammatory agent that crosses the blood-brain barrier. Garcinoic acid also enhances efferocytosis and enzyme/receptor regulation, and selectively inhibits human COX-2, porcine α-amylase, Saccharomyces cerevisiae α-glucosidase and human DNA polymerase β (IC50=11 μM), as well as activates human PXR. Garcinoic acid enhances macrophage efferocytosis via receptors such as MerTK and LRP-1, and promotes the production of pro-resolving lipid mediators. Garcinoic acid inhibits NF-κB activation and pro-inflammatory cytokine secretion, interferes with Aβ aggregation, downregulates NLRP3 inflammasome activity, and binds to targets including CD44 and EGFR to inhibit leukemia cell proliferation. The pharmacological activities of Garcinoic acid, such as antioxidant, anti-inflammatory and lipid metabolism-regulating effects, are widely used in studies related to various diseases including atherosclerosis, Alzheimer's disease, type 2 diabetes, inflammatory bowel disease and viral pneumonia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Wallert M, et al. The vitamin E derivative garcinoic acid from Garcinia kola nut seeds attenuates the inflammatory response. Redox Biol. 2019;24:101166. [Content Brief]
- [2]. Lv P, et al. Therapeutic Properties, Anti-Diabetic Effects, and Anti-Leukemia Cancer Effects of Garcinoic Acid: A Biochemical Approach for Drug Design[J]. 2025.
- [3]. Isot I, et al. Garcinoic acid enhances inflammation resolution against colitis by activating Nrf2 dependent efferocytosis. Free Radic Biol Med. 2025;237:37-45. [Content Brief]
- [4]. Olajide OA, et al. Garcinia kola and garcinoic acid suppress SARS-CoV-2 spike glycoprotein S1-induced hyper-inflammation in human PBMCs through inhibition of NF-κB activation. Phytother Res. 2021;35(12):6963-6973. [Content Brief]
- [5]. Bartolini D, et al. Garcinoic Acid Is a Natural and Selective Agonist of Pregnane X Receptor. J Med Chem. 2020;63(7):3701-3712. [Content Brief]
- [6]. Marinelli R, et al. Garcinoic acid prevents β-amyloid (Aβ) deposition in the mouse brain. J Biol Chem. 2020;295(33):11866-11876. [Content Brief]
- [7]. Sabbatini S, et al. Modulation of C. albicans-Induced Immune Response in Vaginal Epithelial Cells by Garcinoic Acid. Microorganisms. 2024 Nov 29;12(12):2455. [Content Brief]
Keywords
